公开(公告)号：US20200022946A1

公开(公告)日：2020-01-23

申请号：US16557379

申请日：2019-08-30

申请人： THERAPIX BIOSCIENCES, LTD.

发明人： Ephraim Brener ,  Elran Haber ,  Ascher Shmulewitz

IPC分类号： A61K31/352 ,  A61K36/185 ,  A61K31/164 ,  A61P29/00 ,  A61P25/00 ,  A61P25/14 ,  A61P25/30 ,  A61K45/06

摘要： The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

公开(公告)号：US20190307706A1

公开(公告)日：2019-10-10

申请号：US16354070

申请日：2019-03-14

申请人： Bioelectron Technology Corporation

发明人： Paul MOLLARD ,  Christopher R. CORNELL ,  Kieron E. WESSON ,  Peter GIANNOUSIS ,  Shazad SUCHIT ,  Mahmoud MIRMEHRABI

IPC分类号： A61K31/122 ,  C07C215/08 ,  A61K31/164 ,  C07C235/78 ,  C07C215/28 ,  C07B57/00 ,  C07C231/12 ,  C07C215/30

摘要： Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

公开(公告)号：US20190290609A1

公开(公告)日：2019-09-26

申请号：US16436143

申请日：2019-06-10

申请人： EPITECH GROUP S.P.A.

发明人： Francesco DELLA VALLE ,  Maria Federica DELLA VALLE

IPC分类号： A61K31/221 ,  A61K9/16 ,  A61K31/164 ,  A61K31/7034 ,  A61K9/00

摘要： It is the object of the present invention a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide for the control of the inflammatory and/or neuropathic pain of various origin. In particular, the present invention relates to a pharmaceutical composition comprising palmitoylethanolamide (PEA and L-acetylcarnitine (LAC), optionally with in addition an antioxidant compound such as a polyphenol, alpha-lipoic acid, and L-acetylcysteine.

公开(公告)号：US10407382B2

公开(公告)日：2019-09-10

申请号：US15899867

申请日：2018-02-20

申请人： ALLERGAN, INC.

发明人： David W. Old ,  Christopher D. Hein

IPC分类号： C07C235/40 ,  C07C233/63 ,  A61K31/164

摘要： Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.

公开(公告)号：US10350179B2

公开(公告)日：2019-07-16

申请号：US15577439

申请日：2016-05-31

申请人： Raffaele MIGLIACCIO

发明人： Raffaele Migliaccio ,  Antonella Sardei ,  Carmela Migliaccio

IPC分类号： A61K31/164 ,  A61K31/01 ,  A61P29/00

摘要： The object of the present invention is the combination of palmitoylethanolamide (PEA) and lycopene, and/or pharmaceutically acceptable salts and/or derivatives thereof, the pharmaceutical formulations comprising the combination of PEA and lycopene, and/or pharmaceutically acceptable salts or derivatives thereof, optionally together with at least one pharmacologically acceptable excipient, and the use of the combination of PEA and lycopene, and/or pharmaceutically acceptable salts or derivatives thereof, and of the formulations comprising such a combination, in the treatment of inflammatory diseases.

公开(公告)号：US20190195862A1

公开(公告)日：2019-06-27

申请号：US16229176

申请日：2018-12-21

申请人： THE BROAD INSTITUTE, INC. ,  DANA-FARBERCANCER INSTITUTE, INC

发明人： DAVID K. THOMAS ,  TODD R. GOLUB

IPC分类号： G01N33/50 ,  A61P3/00 ,  A61K39/395 ,  G01N33/53 ,  A61K38/00 ,  C07K16/28 ,  A61K31/506 ,  A61K31/454 ,  A61K31/164 ,  A61K31/05 ,  A61K45/06 ,  A61K38/17 ,  G01N33/68 ,  A61K31/519 ,  A61K31/7068

CPC分类号： G01N33/5061 ,  A61K31/05 ,  A61K31/164 ,  A61K31/454 ,  A61K31/506 ,  A61K31/519 ,  A61K31/7068 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P3/00 ,  C07K16/2803 ,  G01N33/5067 ,  G01N33/53 ,  G01N33/5308 ,  G01N33/6893 ,  G01N2800/04 ,  G01N2800/52 ,  G01N2800/60 ,  A61K2300/00

摘要： The invention provides markers indicative of pre-cachexia, compositions and methods for identifying patients with a molecular signature indicative of pre-cachexia; a culture system that reproduces the cachetic process in cells in vitro, which facilitates the screening and identification of therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing) the progression of pre-cachexia to refractory cachexia; as well as therapeutic agents identified using the culture system of the invention.

公开(公告)号：US20190192452A1

公开(公告)日：2019-06-27

申请号：US16260989

申请日：2019-01-29

申请人： The Board of Trustees of the Leland Stanford Junior University ,  THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS ,  THE JOHNS HOPKINS UNIVERSITY

发明人： Mark R. Nicolls ,  Jayakumar Rajadas ,  Geoffrey C. Gurtner ,  Xinguo Jiang ,  Gundeep Dhillon ,  Gregg L. Semenza

IPC分类号： A61K31/164 ,  A61K9/51 ,  A61K31/436 ,  A61K31/4196 ,  A61K31/4412 ,  A61K45/06

CPC分类号： A61K31/164 ,  A61K9/5123 ,  A61K9/5138 ,  A61K9/5146 ,  A61K9/5161 ,  A61K9/5169 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/4412 ,  A61K45/06

摘要： Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.

公开(公告)号：US10300028B2

公开(公告)日：2019-05-28

申请号：US15124321

申请日：2014-07-01

申请人： Mark Tuffley

发明人： Mark Tuffley

IPC分类号： A61K9/00 ,  A61K31/19 ,  A61K31/51 ,  A61K31/59 ,  A61K33/00 ,  A61K33/04 ,  A61K33/06 ,  A61K33/10 ,  A61K33/14 ,  A61K33/18 ,  A61K33/24 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K45/06 ,  A61K31/145 ,  A61K31/155 ,  A61K31/164 ,  A61K31/185 ,  A61K31/197 ,  A61K31/375 ,  A61K31/525 ,  A61K31/198 ,  A61K31/205 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/519 ,  A61K31/714 ,  A61K31/555 ,  A61K31/7004 ,  A61K31/733

摘要： The invention relates to a composition for enhancing wound healing and/or for reducing pain and inflammation, comprising a first active ingredient and a second active ingredient, wherein the first active ingredient comprises an antiseptic and the second active ingredient comprises an admixture of at least one vitamin, at least one mineral and at least one amino acid, and to use of the composition for enhancing wound healing.

公开(公告)号：US20190106392A1

公开(公告)日：2019-04-11

申请号：US16026651

申请日：2018-07-03

申请人： REGENACY PHARACEUTICALS, LLC

发明人： Olga Golonzhka ,  Matthew B. Jarpe

IPC分类号： C07D239/42 ,  A61K31/505 ,  A61K31/164 ,  A61K31/337 ,  A61K31/495

摘要： The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor.

公开(公告)号：US20190060220A1

公开(公告)日：2019-02-28

申请号：US15966674

申请日：2018-04-30

申请人： Richard Postrel

发明人： Richard Postrel

IPC分类号： A61K9/00 ,  A61K31/352 ,  A61K9/70 ,  A61K9/06 ,  A61K31/164 ,  A61K45/06

摘要： This invention provides compositions and methods for cellular regeneration and more rapid healing of surface lesions such as cuts, abrasions, rashes and other skin disturbances. A preferred consumer-based and battlefield embodiment features a spray-on composition delivering at least one substance that stimulates intercellular communication using tunneling nanotubes (TNTs). The induced TNTs increase transport of chemical and/or electrochemical information between more stable and nascent cells or between more intact and damaged cells. The inventive substance is applicable for use for ordinary household type injuries as well as industrial and/or battlefield events, perhaps from physical or chemical accidents or even several types of chemical weapons. Another preferred embodiment incorporates a sealant composition or coating to shield the affected surface area designated for healing from contamination and further damage, e.g., microbial, contact pressure, solar and other sources of radiation, etc.